Paykel E S, White J L
University of Cambridge, Addenbrooke's Hospital, UK.
Br J Psychiatry Suppl. 1989 Oct(6):9-17.
A total of 1269 psychiatrists, from 15 European countries, completed a questionnaire assessing treatment choice in depressive and anxiety disorders, with particular focus on diagnostic and other factors determining use of monoamine oxidase inhibitors (MAOIs). Tricyclic and similar antidepressants were used most commonly--MAOIs were used as first-choice therapy for depressive or anxiety disorders only by a minority but were commonly a second-choice treatment for atypical depressives. Use was inhibited by interactions and side-effects rather than by perceived ineffectiveness. Cross-national differences in treatment were considerable but diagnostic differences in case history vignettes were much smaller.
来自15个欧洲国家的1269名精神科医生完成了一份问卷，该问卷评估了抑郁和焦虑症的治疗选择，特别关注决定单胺氧化酶抑制剂（MAOIs）使用的诊断及其他因素。三环类及类似抗抑郁药使用最为普遍——MAOIs仅被少数人用作抑郁或焦虑症的首选治疗方法，但通常是不典型抑郁症的二线治疗方法。其使用受到相互作用和副作用的限制，而非疗效不佳。各国在治疗方面存在相当大的差异，但病例 vignettes中的诊断差异要小得多。
